LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Charles River Laboratories International Inc

Fermé

SecteurSoins de santé

157.95 -2.39

Résumé

Variation du prix de l'action

24h

Actuel

Min

153.91

Max

163.94

Chiffres clés

By Trading Economics

Revenu

27M

53M

Ventes

48M

1B

P/E

Moyenne du Secteur

592.3

35.733

Marge bénéficiaire

5.105

Employés

18,700

EBITDA

37M

221M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+6.9% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-275M

8B

Ouverture précédente

160.34

Clôture précédente

157.95

Sentiment de l'Actualité

By Acuity

76%

24%

345 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Charles River Laboratories International Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 sept. 2025, 23:37 UTC

Actions en Tendance

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 sept. 2025, 20:41 UTC

Résultats

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 sept. 2025, 20:30 UTC

Résultats

GameStop 2Q Sales, Profit Rise

9 sept. 2025, 23:19 UTC

Market Talk

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 sept. 2025, 21:35 UTC

Résultats

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept. 2025, 21:32 UTC

Résultats

Oracle's Backlog Swells With Big Customer Deals -- Update

9 sept. 2025, 21:02 UTC

Acquisitions, Fusions, Rachats

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 sept. 2025, 20:33 UTC

Résultats

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 sept. 2025, 20:26 UTC

Résultats

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept. 2025, 20:23 UTC

Résultats

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept. 2025, 20:12 UTC

Résultats

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 sept. 2025, 20:10 UTC

Résultats

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 sept. 2025, 20:10 UTC

Résultats

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 sept. 2025, 20:09 UTC

Résultats

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 sept. 2025, 20:09 UTC

Résultats

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 sept. 2025, 20:08 UTC

Résultats

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 sept. 2025, 20:08 UTC

Résultats

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 sept. 2025, 20:08 UTC

Résultats

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 sept. 2025, 20:08 UTC

Résultats

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 sept. 2025, 20:07 UTC

Résultats

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 sept. 2025, 20:06 UTC

Résultats

Oracle 1Q Software Revenue $5.72B >ORCL

9 sept. 2025, 20:06 UTC

Résultats

Synopsys 3Q Adj EPS $3.39 >SNPS

9 sept. 2025, 20:06 UTC

Résultats

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 sept. 2025, 20:05 UTC

Résultats

Oracle 1Q Rev $14.93B >ORCL

9 sept. 2025, 20:05 UTC

Résultats

Oracle 1Q EPS $1.01 >ORCL

9 sept. 2025, 20:05 UTC

Résultats

Synopsys 3Q EPS $1.50 >SNPS

9 sept. 2025, 20:05 UTC

Résultats

Oracle 1Q Services Revenue $1.35B >ORCL

9 sept. 2025, 20:05 UTC

Résultats

Oracle 1Q Adj EPS $1.47 >ORCL

9 sept. 2025, 20:05 UTC

Résultats

Oracle 1Q Hardware Revenue $670M >ORCL

Comparaison

Variation de prix

Charles River Laboratories International Inc prévision

Objectif de Prix

By TipRanks

6.9% hausse

Prévisions sur 12 Mois

Moyen 173.18 USD  6.9%

Haut 195 USD

Bas 151 USD

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

13 ratings

5

Achat

8

Maintien

0

Vente

Score Technique

By Trading Central

117.16 / 144.77Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

345 / 371Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat